Fig. 1
MRTX1133 (30 mg/kg) reduces tumor growth in a HG-PMP xenograft mouse model. (A–C) Abdominal girth (normalized by body weight gain), mucinous tumor weight (g) and pre/post-treatment mouse weight gain (calculated as the difference between the pre-treatment mouse weight and the weight before sacrifice) measured after sacrifice in MRTX1133-treated (n = 18) and control mice (n = 19). (D) Quantification of an estimated mucinous tumor volume (mm3) within mouse peritoneum using MRI T2-weighted images in treated (n = 18) and control mice (n = 19). (E) Representative MRI T2-weighted images of MRTX1133-treated and control mice. Mucin appears as hypointense regions in the images. (F) Representative 3D images of mouse abdomens showing the distribution of mucin within peritoneumin treated and control mice. Mucin appears highlighted in yellow in the images. (G) Representative images of a control (left images) and a MRTX1133-treated mouse (right images) at sacrifice. Mucin appears as a viscous liquid throughout the peritoneum in control mice. Data are represented as the mean ± SEM. ** p < 0.001.